{"name":"Curis","slug":"curis","ticker":"CRIS","exchange":"NASDAQ","domain":"curis.com","description":"Selagis is a genus of beetles in the family Buprestidae.","hq":"Lexington, MA","founded":0,"employees":"20","ceo":"James Dentzer","sector":"Oncology","stockPrice":0.51,"stockChange":0.01,"stockChangePercent":2,"marketCap":"$21M","metrics":{"revenue":9898000,"revenueGrowth":203.4,"grossMargin":0,"rdSpend":18000000,"netIncome":-7582000,"cash":15001000,"dividendYield":0,"peRatio":-0.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Zynyz patent cliff ($100M at risk)","drug":"Zynyz","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Curis Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Curis reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $34.4 million and $143.6 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Curis Announces Collaboration with National Cancer Institute to Develop Novel Cancer Therapies","summary":"Curis entered into a collaboration with the National Cancer Institute to develop novel cancer therapies, further expanding its pipeline and capabilities.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNekNPYXhzRFpEZ25MVkFMRGh1dzNQbVhDdTc0bmlqTHZiT3huY3U3alVLVWprU0p2RF9xT2dmbk90enBjem5xUkNfX2VPSG5wcFh1QUNkRkJBWTZ1LU1NcG13M0g3cHUtbmtBU1Fvc2p6SXo5Zm85TUtHUWFZeW9IeXNTNGRad2Y3RHBLa0dyNXluUjRkaGdmTzhLc1hIXzM2TUhLd2xwQkZJZ2NCek9TajNoMDI0N0NSc1JyWUZOOHg?oc=5","date":"2026-01-08","type":"pipeline","source":"AD HOC NEWS","summary":"Curis Inc: Can This Beaten-Down Cancer Stock Still Surprise The Market? - AD HOC NEWS","headline":"Curis Inc: Can This Beaten-Down Cancer Stock Still Surprise The Market?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVEJDTGpSVkFvdXhMOTZTeUJXSzluNndhclNRa1lsNnlqdUkyY2c4a0pEVVQwTWViT2FiVGhnNlNxOEszcDl3VzJqRVE5el94TkdTMnRlanNrVFVEMmVHZER1TTI3UDFQZlBZemtCZXBjU2FLSWQwU2I1SE9RMUxHeEx2SmlIWWwxT0ZyeXJQZVJfcGdBTi1CS0taU0JTVHpTMHpHZXV0bnRWcERRX1ZCc2UtdG1lYlFaYVdUUXU0R0dJNGwxR0FjbFQweVNtajF6d1NVM0EzNFljZ0NqSHpJ?oc=5","date":"2026-01-07","type":"pipeline","source":"PR Newswire","summary":"Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - PR Newswire","headline":"Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-04","type":"pipeline","source":"simplywall.st","summary":"Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge - simplywall.st","headline":"Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOX0YyOExpUDluRURobGc0U0Q5aW5aNEZaVWxVY0FzUjBTd0lwdHhGZGxDMk1NRE9nTGpnZ25rWkZOU051ZFZRX2E4OXZYa2R3V1FfaUduY1RSdTc3WjR6Q3JWSXh2Y2F4TWF6eHBRS3J4NnhMbmJxcXdpUmtEaGdERW56LVpzcUFRV0dOUHNKZjNodjZGcmZlSVJWLUNKVjA5SXgxbTVmVGVPZ2NjbXZCMWxYc3d1a0pUUmFMQQ?oc=5","date":"2025-12-09","type":"trial","source":"PR Newswire","summary":"Curis Provides Updated Data from its Frontline AML Triplet Study - PR Newswire","headline":"Curis Provides Updated Data from its Frontline AML Triplet Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOR0c4TU9LcC1yOTdaUHAxSWJUYXhBcm1VLVdxUnRYa29iWFFvZG5BWllxV014c1M0ZnpIanVPdmVWSzdDMENscHhETlNrUW9wLURuWnh1WGUyUmt0LWZicjYwUXd6UTNUOWtlblNFRDFGSDY2aDZqTWFSSlNnZ19DWktEanEtWWY5UXBaRjU2dGh3ZmtLaXgwbmpSUktPUXlBdWw3TDBYRTI?oc=5","date":"2025-11-06","type":"earnings","source":"PR Newswire","summary":"Curis Provides Third Quarter 2025 Business Update - PR Newswire","headline":"Curis Provides Third Quarter 2025 Business Update","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-08","type":"pipeline","source":"simplywall.st","summary":"Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target - simplywall.st","headline":"Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSFZuZWhvSzRFcTdUOXhoNW1nODZDenQ5ZXdDVW8yM3FoNE84c0hlX1M2eXlPY1VHQmMwdnVFTm9DRmlqdnk4RnlpV2k0cEJRQzQ0dHdNcWRwMzY2U3duT1hMcDhmcWtYa1YwdTZmS0dNdHlpMElCUDhmc3VoV3lFNjFwMmF5YUVDbkhoak04b1BjTlp5M0tWWkg4RFdtSkt6RXhUUDVrS1JXUQ?oc=5","date":"2025-08-05","type":"earnings","source":"PR Newswire","summary":"Curis Provides Second Quarter 2025 Business Update - PR Newswire","headline":"Curis Provides Second Quarter 2025 Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQV0hEY09GaUZOUEVPUmJzdEc2cFgtekVQZVZlTzVneTBKQndDYkpjSmVUQ0RqN2dqYldfRlR6NWRLVTk1b3lwLVpMeVI3YW80MUx0bnA0Szlab2sxNkVuc0w2NVJES1BGV3ZsVURDREJrN3g1VFRnQ3FtN0hfOFBMTXVtZG5FaG95RHZyWldfMVlBcFZNWkN1OXFQaFZTRWRDdG9YRmxYbXgtT1pVdTduQkVJLWpwZHNQUGNiYmJOT09TMVVDaVRTUFg1U3hUalE?oc=5","date":"2025-07-02","type":"pipeline","source":"PR Newswire","summary":"Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement - PR Newswire","headline":"Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPNUNBTjRSNmxESUVRZ000OE54WUpxbGhDRFhkU1FYSkdlVUVNdEk5RFlyc0pPTlNvQVBaVmgzMHFnd1hFUDd5aEFVdnZmVDI0aG1HZk5NTVdGYlI5elJRdkM5ZXBTRGpJeFkwWFRfeEctMkN3WU9Rbi1QOU1ET252LUVEZ05pUVAxdlkzcl9BRnVmNC1VbFpTeURBQTQxRlI4eldXWFFucXo4UQ?oc=5","date":"2025-03-31","type":"earnings","source":"PR Newswire","summary":"Curis Provides Fourth Quarter 2024 Business Update - PR Newswire","headline":"Curis Provides Fourth Quarter 2024 Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdmpNZW9PeldNMHF2bHJ2YlZIZFkxZmxRWGZod2libHVmN1BIdXY3a3dwelZkQXZJSDJTOS1IYVRaMlFEUnlyVjl5N2NHbzI4RzN6V09BQ1J1ZER5OXg1bzNYOW9PTjRObkV3WXRjNFFMVVpIYmF2QndWRzJtcnhfaEx6WDRJc250bmZ0X1BGWi1fRm1IWXhmd3pkX1hUeWhlMFhsVS1XZ3ROMnVaZGlPM0JlUDdMdw?oc=5","date":"2024-12-10","type":"trial","source":"PR Newswire","summary":"Curis Announces Additional Data from TakeAim Leukemia Study - PR Newswire","headline":"Curis Announces Additional Data from TakeAim Leukemia Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOVXJuY2h6THBSakdtYXpWdVpZOTJRQm1TUWRfUVE0bWlRa1VuNXlMeVd3RnhFRUh2cEN0S2x4QWF1dVVoeGtkZjlvSGR2S3M3OXNJUFB4eUZDZmtHTlJRLTV6c0JfUmZRTUE3VkRuRlcxTnZycFpielgtUC1oQUpfOVp2Zkt1dEJqQU1fWG1FOEVjbU5nb1NxaXNQdmM5blp0bkpQOHhlbHdQRHI2QjNkc0RYNHZiZXZkSXJHLV93LVh6THFuNllMNzhESThTX1VNVkk0LVVyTkRJVUZXQlZ1QWkxNHlPcEl4SVRxRUZyZlJvMmNa?oc=5","date":"2020-02-06","type":"deal","source":"PR Newswire","summary":"Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 - PR Newswire","headline":"Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170","sentiment":"neutral"}],"patents":[{"drugName":"Zynyz","drugSlug":"umbralisib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Hematology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":9898000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":9898000,"period":"2017-12-31"},{"value":3262000,"period":"2017-12-31"},{"value":2444000,"period":"2017-09-30"},{"value":2061000,"period":"2017-06-30"},{"value":2131000,"period":"2017-03-31"}],"grossProfit":9398000,"grossProfitHistory":[{"period":"2025-12-31","value":9398000},{"period":"2024-12-31","value":10810000},{"period":"2023-12-31","value":9811000},{"period":"2022-12-31","value":9905000}],"rdSpend":18000000,"rdSpendHistory":[{"period":"2025-12-31","value":28254000},{"period":"2024-12-31","value":38562000},{"period":"2023-12-31","value":39496000},{"period":"2022-12-31","value":43277000}],"sgaSpend":14046000,"operatingIncome":-32902000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-32902000},{"period":"2024-12-31","value":-44542000},{"period":"2023-12-31","value":-48332000},{"period":"2022-12-31","value":-53020000}],"netIncome":-7582000,"netIncomeHistory":[{"period":"2025-12-31","value":-7582000},{"period":"2024-12-31","value":-43389000},{"period":"2023-12-31","value":-47413000},{"period":"2022-12-31","value":-56672000}],"eps":-6.88,"epsHistory":[{"period":"2024-12-31","value":-6.88},{"period":"2023-12-31","value":-8.96},{"period":"2022-12-31","value":-12.2},{"period":"2021-12-31","value":-10}],"cash":5061000,"cashHistory":[{"period":"2025-12-31","value":5061000},{"period":"2024-12-31","value":19997000},{"period":"2023-12-31","value":26681000},{"period":"2022-12-31","value":19658000}],"totalAssets":19966000,"totalLiabilities":14504000,"totalDebt":1618000,"equity":5462000,"operatingCashflow":-27201000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-27201000},{"period":"2024-12-31","value":-39563000},{"period":"2023-12-31","value":-38434000},{"period":"2022-12-31","value":-54337000}],"capex":-416000,"capexHistory":[{"period":"2022-12-31","value":-416000}],"freeCashflow":-27201000,"dividendsPaid":null,"buybacks":null,"employees":20,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2883000,"ebit":19935000,"ebitda":19971000,"period":"2025-12-31","revenue":1138000,"epsBasic":1.23,"netIncome":19356000,"rdExpense":5825000,"epsDiluted":1.23,"grossProfit":1138000,"operatingIncome":-7570000},{"sga":3653000,"ebit":-6924000,"ebitda":-6892000,"period":"2025-09-30","revenue":3176000,"epsBasic":-0.49,"netIncome":-7729000,"rdExpense":6432000,"epsDiluted":-0.49,"grossProfit":3161000,"operatingIncome":-6924000},{"sga":3526000,"ebit":-8251000,"ebitda":-8209000,"period":"2025-06-30","revenue":2749000,"epsBasic":-0.68,"netIncome":-8593000,"rdExpense":7458000,"epsDiluted":-0.68,"grossProfit":2733000,"operatingIncome":-8251000},{"sga":3984000,"ebit":-10157000,"ebitda":-10098000,"period":"2025-03-31","revenue":2380000,"epsBasic":-1.25,"netIncome":-10616000,"rdExpense":8539000,"epsDiluted":-1.25,"grossProfit":2366000,"operatingIncome":-10157000},{"sga":3354000,"ebit":-7226000,"ebitda":-7210000,"period":"2024-12-31","revenue":3345000,"epsBasic":-1.25,"netIncome":-9618000,"rdExpense":8968000,"epsDiluted":-1.25,"grossProfit":3328000,"operatingIncome":-8994000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.51,"previousClose":0.5,"fiftyTwoWeekHigh":3.13,"fiftyTwoWeekLow":0.49,"fiftyTwoWeekRange":"0.49 - 3.13","fiftyDayAverage":0.68,"twoHundredDayAverage":1.18,"beta":0,"enterpriseValue":-3982261,"forwardPE":-0.5,"priceToBook":1.22,"priceToSales":2.91,"enterpriseToRevenue":-0.56,"enterpriseToEbitda":0.12,"pegRatio":0,"ebitda":-34111752,"ebitdaMargin":0,"freeCashflow":0,"operatingCashflow":0,"totalDebt":1337000,"debtToEquity":10.5,"currentRatio":1.22,"returnOnAssets":-62.1,"returnOnEquity":-693.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":14,"targetHighPrice":20,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3,"institutionHeldPercent":24.3,"sharesOutstanding":39978693,"floatShares":16034702,"sharesShort":262332,"shortRatio":0.35,"shortPercentOfFloat":0.7,"epsTrailing":-0.58,"epsForward":-0.96,"revenuePerShare":0.45,"bookValue":0.42,"officers":[{"age":58,"name":"Mr. James E. Dentzer","title":"President, CEO, Secretary, Treasurer & Director"},{"age":53,"name":"Ms. Diantha  Duvall CPA, M.B.A.","title":"CFO and Principal Financial & Accounting Officer"},{"age":59,"name":"Dr. Jonathan B. Zung Ph.D.","title":"Chief Development Officer"},{"age":66,"name":"Mr. Mark W. Noel","title":"Vice President of Technology Management & Intellectual Property"},{"age":62,"name":"Dr. Robert E. Martell M.D., Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Nancy  Soohoo","title":"VP & General Counsel"},{"age":null,"name":"Ms. Rachel  Blasbalg","title":"Senior Director of Human Resources"},{"age":60,"name":"Dr. Ahmed M. Hamdy M.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"http://investors.curis.com/","website":"https://www.curis.com","phone":"617 503 6500"}}